We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Plasma CD24 level as a promising prognostic biomarker of hepatocellular carcinoma.
- Authors
Rasmy, Hany Samir; Awad, Emad Ahmad; Mohamed, Eslam Safwat; Boshra, Amal Samy; Ibrahim, Shereen Abdel Monem; Isaac, Amira
- Abstract
Background: Hepatocellular carcinoma constitutes the most common primary hepatic cancer and remains a major medical burden in both developing and developed world. It ranks fifth in terms of global cases and second in terms of deaths for males.CD24 is known as a heavily glycosylated cell surface molecule that is highly expressed in a wide variety of human malignancies. It plays an important role in self-renewal, proliferation, migration, invasion, and drug resistance. The aim of this work was to evaluate the potential role of serum CD24 in the diagnosis and prediction of response to interventional therapy among hepatocellular carcinomas. Methods: This study included 40 adult Egyptian patients who had liver cirrhosis and hepatocellular carcinoma (HCC group). Another group of 20 patients with liver cirrhosis only served as controls (Cirrhosis group). All patients underwent standard laboratory tests and abdominal ultrasound. For HCC patients, a triphasic CT scan, alpha-fetoprotein was done. CD24 levels were measured in all patients, and in HCC patients at baseline and one month after intervention. Results: Baseline CD24 was significantly higher among HCC group in comparison to cirrhosis group (19.463 ± 8.573 vs. 0.725 ± 0.125 mg/L) with an overall p value < 0.001. Serum CD24 levels significantly declined after locoregional treatment from 19.463 ± 8.573 mg/L to 3.569 ± 1.248 mg/L (p < 0.001). Baseline CD24 was a useful marker in eligibility for HCC intervention with 80% sensitivity and 74.29% specificity at a cutoff of ≤ 23 mg/L, and it also had 62.96% sensitivity and 100% specificity in prediction of cure after locoregional treatment at a cutoff of ≤ 19.5 mg/L. Conclusion: CD24 could be a helpful diagnostic and prognostic marker for HCC, as its baseline level is useful in predicting both eligibility for intervention and cure after locoregional treatment.
- Subjects
BIOMARKERS; EGYPTIANS; PROGNOSIS; CIRRHOSIS of the liver; COMPUTED tomography; HEPATOCELLULAR carcinoma
- Publication
Egyptian Liver Journal, 2024, Vol 14, Issue 1, p1
- ISSN
2090-6218
- Publication type
Article
- DOI
10.1186/s43066-024-00343-6